Exploring the Gut Microbiota: Key Insights Into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39040013/
The gut microbiota (GM), comprising trillions of microorganisms in the gastrointestinal tract, is a key player in the development of obesity and related metabolic disorders, such as type 2 diabetes...
Gut microbiota significantly influences obesity, T2D, and metabolic syndrome through energy metabolism and inflammation; targeting microbiota via diet or therapy shows promise for future treatment strategies.
Dapagliflozin plus calorie restriction significantly increased type 2 diabetes remission rates and improved metabolic parameters over 12 months versus calorie restriction alone, with no increase in adverse events.
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39197881/
SGLT-2 inhibitors might prevent dementia, providing greater benefits with longer treatment. As this study was observational and therefore prone to residual confounding and informative censoring, the effect size could have...
Adults aged 40–69 with type 2 diabetes on SGLT-2 inhibitors had a significantly lower risk of dementia than those on DPP-4 inhibitors, with stronger benefits seen with longer treatment durations.
Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39493275/
Scholarly critiques have explored diverse methodologies of probiotic engineering, including physical alteration, bioenrichment, and genetic manipulation. These techniques augment the therapeutic potency of probiotics by ameliorating gut microbiota, fortifying the...
Engineered probiotics offer a promising diabetes treatment by enhancing gut health and metabolic regulation. This review explores their mechanisms, clinical efficacy, and potential advantages over traditional therapies.
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40100982/
Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to...
Early glycemic or weight response to tirzepatide predicts better long-term metabolic outcomes, including improved HbA1c, weight, blood pressure, and lipids, supporting individualized treatment strategies in type 2 diabetes.